Melendez-Torres, G. J. http://orcid.org/0000-0002-9823-4790
Armoiry, Xavier
Court, Rachel
Patterson, Jacoby
Kan, Alan
Auguste, Peter
Madan, Jason
Counsell, Carl
Ciccarelli, Olga
Clarke, Aileen
Funding for this research was provided by:
Health Technology Assessment Programme (ID809)
Article History
Received: 17 January 2018
Accepted: 21 September 2018
First Online: 3 October 2018
Ethics approval and consent to participate
: This study did not require ethics approval.
: Not applicable.
: Prof. Olga Ciccarelli received consultancy fees from Teva, Roche, Novartis, Biogen Idec, and Genzyme. She also received funds for research from the UK MS Society, National MS Society, EPSRC, Rosetree Trust; her research is supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC). She is an Associate Editor of <i>Neurology</i> for which she receives an honorarium. Dr. Carl Counsell received funding through Biogen Idec, who previously provided some funding for a departmental MS nurse. Dr. Carl Counsell has also authored a paper that was critical of the UK Risk Sharing Scheme for disease modifying therapies in MS (Sudlow, CLM, Counsell, CE. Problems with UK government’s risk sharing scheme for assessing drugs for multiple sclerosis. BMJ 2003; 326:388–392). The remaining authors have no competing interests to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.